JP2010514768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514768A5 JP2010514768A5 JP2009544100A JP2009544100A JP2010514768A5 JP 2010514768 A5 JP2010514768 A5 JP 2010514768A5 JP 2009544100 A JP2009544100 A JP 2009544100A JP 2009544100 A JP2009544100 A JP 2009544100A JP 2010514768 A5 JP2010514768 A5 JP 2010514768A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 7
- 102000014150 Interferons Human genes 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 229940079322 interferon Drugs 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- -1 hydroxyarylalkyl Chemical group 0.000 claims 5
- 239000003443 antiviral agent Substances 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 2
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 claims 2
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims 2
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims 2
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims 2
- 241000710781 Flaviviridae Species 0.000 claims 2
- 229940121759 Helicase inhibitor Drugs 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 claims 2
- ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 claims 2
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 claims 2
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 claims 2
- 229950005984 cerulenin Drugs 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 claims 2
- 229940103893 gliotoxin Drugs 0.000 claims 2
- 229930190252 gliotoxin Natural products 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 150000003548 thiazolidines Chemical class 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- NYPIRLYMDJMKGW-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 NYPIRLYMDJMKGW-VPCXQMTMSA-N 0.000 claims 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical class NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 claims 1
- TVRCRTJYMVTEFS-ICGCPXGVSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C[C@@]1(O)[C@H](OC(=O)[C@@H](N)C(C)C)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 TVRCRTJYMVTEFS-ICGCPXGVSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- 108010080374 albuferon Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 229960005338 clevudine Drugs 0.000 claims 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 108700027921 interferon tau Proteins 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 229950010550 resiquimod Drugs 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229950002810 valopicitabine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
- 0 CC1(C)OC(CO*(N(*)**)OCCCSC(*)=O)=C(*)C1(*)CN(C=CC(N)=N1)C1=O Chemical compound CC1(C)OC(CO*(N(*)**)OCCCSC(*)=O)=C(*)C1(*)CN(C=CC(N)=N1)C1=O 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87794406P | 2006-12-28 | 2006-12-28 | |
| US60/877,944 | 2006-12-28 | ||
| US93629007P | 2007-06-18 | 2007-06-18 | |
| US60/936,290 | 2007-06-18 | ||
| US98589107P | 2007-11-06 | 2007-11-06 | |
| US60/985,891 | 2007-11-06 | ||
| PCT/US2007/026408 WO2008082601A2 (en) | 2006-12-28 | 2007-12-28 | Compounds and pharmaceutical compositions for the treatment of viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014060859A Division JP2014139218A (ja) | 2006-12-28 | 2014-03-24 | ウイルス感染の治療のための化合物、及び医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514768A JP2010514768A (ja) | 2010-05-06 |
| JP2010514768A5 true JP2010514768A5 (enExample) | 2011-01-27 |
| JP5578853B2 JP5578853B2 (ja) | 2014-08-27 |
Family
ID=39589128
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544100A Expired - Fee Related JP5578853B2 (ja) | 2006-12-28 | 2007-12-28 | ウイルス感染の治療のための化合物、及び医薬組成物 |
| JP2009544101A Pending JP2010514769A (ja) | 2006-12-28 | 2007-12-28 | 肝臓障害の治療のための化合物、及び医薬組成物。 |
| JP2014060859A Pending JP2014139218A (ja) | 2006-12-28 | 2014-03-24 | ウイルス感染の治療のための化合物、及び医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544101A Pending JP2010514769A (ja) | 2006-12-28 | 2007-12-28 | 肝臓障害の治療のための化合物、及び医薬組成物。 |
| JP2014060859A Pending JP2014139218A (ja) | 2006-12-28 | 2014-03-24 | ウイルス感染の治療のための化合物、及び医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20080261913A1 (enExample) |
| EP (2) | EP2120566B1 (enExample) |
| JP (3) | JP5578853B2 (enExample) |
| KR (1) | KR101508018B1 (enExample) |
| AU (1) | AU2007339226B2 (enExample) |
| BR (1) | BRPI0720637A2 (enExample) |
| CA (2) | CA2673722A1 (enExample) |
| IL (1) | IL200116A0 (enExample) |
| ME (1) | ME00816B (enExample) |
| MX (1) | MX2009006851A (enExample) |
| MY (1) | MY169568A (enExample) |
| NO (1) | NO20092585L (enExample) |
| NZ (1) | NZ577999A (enExample) |
| RU (1) | RU2525392C2 (enExample) |
| SG (1) | SG177923A1 (enExample) |
| TW (2) | TW200844108A (enExample) |
| UA (1) | UA96975C2 (enExample) |
| WO (2) | WO2008082601A2 (enExample) |
Families Citing this family (182)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| LT1576138T (lt) | 2002-11-15 | 2017-06-26 | Idenix Pharmaceuticals Llc | 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija |
| ATE534652T1 (de) | 2005-04-01 | 2011-12-15 | Univ California | Phosphono-pent-2-en-1-yl-nukleoside und analoga |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| JP5452022B2 (ja) | 2006-12-11 | 2014-03-26 | 独立行政法人科学技術振興機構 | 植物生長調整剤及びその利用 |
| US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008141227A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2009113684A1 (ja) | 2008-03-14 | 2009-09-17 | トヨタ自動車株式会社 | 植物のバイオマス量及び/又は種子量を増産させる遺伝子及びその利用方法 |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| HUE025528T2 (en) | 2008-04-23 | 2016-05-30 | Gilead Sciences Inc | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| TW201004632A (en) * | 2008-07-02 | 2010-02-01 | Idenix Pharmaceuticals Inc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
| US8759318B2 (en) * | 2009-01-09 | 2014-06-24 | Inhibitex, Inc. | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
| MX2011008409A (es) | 2009-02-10 | 2011-10-21 | Gilead Sciences Inc | Análogos de carba-nucléosido para tratamiento antiviral. |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| JP5604657B2 (ja) | 2009-03-12 | 2014-10-08 | トヨタ自動車株式会社 | 植物のバイオマス量及び／又は種子量を増産させる遺伝子及びその利用方法 |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| JP5250807B2 (ja) | 2009-09-11 | 2013-07-31 | トヨタ自動車株式会社 | 植物のバイオマス量及び／又は種子量を増産させる方法、バイオマス量及び／又は種子量を増産できる植物の製造方法 |
| CN102596958A (zh) * | 2009-09-21 | 2012-07-18 | 吉里德科学公司 | 用于抗病毒治疗的2’-氟代carba-核苷类似物 |
| MX2012003126A (es) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
| US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| PH12012501216A1 (en) | 2009-12-18 | 2012-11-05 | Boehringer Ingelheim Int | Hcv combination therapy |
| SG184324A1 (en) * | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| PH12012502210A1 (en) * | 2010-05-18 | 2013-02-04 | Bukwang Pharma Co Ltd | Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil |
| AU2011282241B2 (en) | 2010-07-19 | 2015-07-30 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| BR112013008017A2 (pt) | 2010-09-20 | 2016-06-14 | Gilead Sciences Inc | análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral |
| NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
| WO2012048013A2 (en) * | 2010-10-06 | 2012-04-12 | Inhibitex, Inc. | Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections |
| WO2012051567A2 (en) * | 2010-10-15 | 2012-04-19 | The Trustees Of Columbia University In The City Of New York | Obesity-related genes and their proteins and uses thereof |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| US20120164120A1 (en) * | 2010-12-23 | 2012-06-28 | Food Industry Research And Development Institute | Novel monascuspurpurones, preparation process thereof, and uses of the monascuspurpurones |
| EP2658857B1 (en) * | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| EP2680859B1 (en) | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| US8877733B2 (en) | 2011-04-13 | 2014-11-04 | Gilead Sciences, Inc. | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment |
| CA2847892A1 (en) * | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| WO2013066991A1 (en) * | 2011-10-31 | 2013-05-10 | Inhibitex, Inc. | Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| WO2013084165A1 (en) * | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
| KR101703180B1 (ko) | 2011-12-12 | 2017-02-06 | 오카야마켄 | 식물의 아미노산 함량을 높이기 위한 화합물 및 그 이용 |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
| US8673926B2 (en) | 2012-02-14 | 2014-03-18 | University Of Georgia Research Foundation, Inc. | Spiro[2.4]heptanes for treatment of flaviviridae infections |
| RU2014133467A (ru) * | 2012-02-17 | 2016-04-10 | Селшн Корпорейшн | Термочувствительные составы в виде наночастиц и способ их получения |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| JP6165848B2 (ja) | 2012-05-22 | 2017-07-19 | イデニク ファーマシューティカルズ エルエルシー | 肝疾患のためのｄ−アミノ酸化合物 |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| CN104640444B (zh) * | 2012-06-16 | 2016-12-14 | 河南美泰宝生物制药有限公司 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| EP2906579B1 (en) | 2012-10-08 | 2018-04-18 | Idenix Pharmaceuticals LLC. | 2'-chloro nucleoside analogs for hcv infection |
| JP2015534464A (ja) | 2012-10-09 | 2015-12-03 | カリフォルニア インスティチュート オブ テクノロジー | ヘム酵素によって触媒されるインビボおよびインビトロオレフィンシクロプロパン化 |
| WO2014058729A1 (en) * | 2012-10-09 | 2014-04-17 | California Institute Of Technology | In vivo and in vitro carbene insertion and nitrene transfer reactions catalyzed by heme enzymes |
| EP2909209B1 (en) | 2012-10-17 | 2022-08-03 | Merck Sharp & Dohme LLC | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| JP2016501200A (ja) * | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ウイルス性疾患を処置するための２−アルキニル置換ヌクレオシド誘導体 |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| CN103012520B (zh) * | 2012-12-28 | 2015-12-02 | 中国科学院上海有机化学研究所 | 抗乙肝病毒活性化合物菲糖苷类衍生物 |
| US20140212355A1 (en) * | 2013-01-28 | 2014-07-31 | Abbott Cardiovascular Systems Inc. | Trans-arterial drug delivery |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| US9765107B2 (en) | 2013-06-18 | 2017-09-19 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| AU2014302711A1 (en) | 2013-06-26 | 2015-12-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| MX2015017556A (es) | 2013-06-26 | 2016-05-09 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos. |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| LT3043803T (lt) | 2013-09-11 | 2022-08-10 | Emory University | Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015054465A1 (en) | 2013-10-11 | 2015-04-16 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015056213A1 (en) | 2013-10-17 | 2015-04-23 | Medivir Ab | Hcv polymerase inhibitors |
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| US9399762B2 (en) | 2014-02-18 | 2016-07-26 | California Institute Of Technology | Methods and systems for sulfimidation or sulfoximidation of organic molecules |
| US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| US11918728B2 (en) | 2014-04-17 | 2024-03-05 | ImMutriX Therapeutics, Inc. | Therapeutic compositions for viral-associated disease states and methods of making and using same |
| US9669151B2 (en) | 2014-04-17 | 2017-06-06 | ImMutriX Therapeutics, Inc. | Therapeutic compositions for viral-associated disease states and methods of making and using same |
| KR20170005492A (ko) * | 2014-05-28 | 2017-01-13 | 아이데닉스 파마슈티칼스 엘엘씨 | 암의 치료를 위한 뉴클레오시드 유도체 |
| HUE051986T2 (hu) | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| EP3170829B1 (en) | 2014-07-18 | 2018-09-19 | JW Pharmaceutical Corporation | Novel salt of tenofovir disoproxil |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| WO2016173487A1 (en) * | 2015-04-26 | 2016-11-03 | Cheng-Jui Lin | Method for improving kidney and/or heart function in patients with kidney disease |
| DK3785717T3 (da) | 2015-09-16 | 2022-03-21 | Gilead Sciences Inc | Fremgangsmåder til behandling af coronaviridae-infektioner |
| MX391226B (es) | 2015-09-23 | 2025-03-21 | Merck Sharp & Dohme Llc | Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. |
| RU2657833C2 (ru) | 2015-12-01 | 2018-06-15 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| BR112018072559A2 (pt) * | 2016-05-02 | 2019-02-19 | Paratek Pharmaceuticals, Inc. | método de tratar infecção do trato urinário. |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3471737B1 (en) | 2016-06-20 | 2025-06-04 | Merck Sharp & Dohme LLC | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| WO2017221929A1 (ja) * | 2016-06-21 | 2017-12-28 | 株式会社ジーンデザイン | リボ核酸ｈ－ホスホネートモノマーの合成方法および本モノマーを用いたオリゴヌクレオチド合成 |
| RU2632431C2 (ru) * | 2016-06-29 | 2017-10-04 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Гидрогель для получения композиционных материалов с антибактериальной активностью для замещения костно-хрящевых дефектов методом 3d печати |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| EA030671B1 (ru) | 2016-07-20 | 2018-09-28 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Препарат для лечения костных поражений, вызванных злокачественными новообразованиями |
| EP3500294A4 (en) | 2016-08-22 | 2020-07-29 | Arbutus Biopharma Corporation | ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B |
| WO2018048937A1 (en) * | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| WO2018071814A1 (en) | 2016-10-14 | 2018-04-19 | The Trustees Of Columbia University In The City Of New York | Methods of treating alcohol abuse disorder |
| BR112019008897A2 (pt) | 2016-11-01 | 2019-08-13 | Paratek Pharm Innc | método para tratar pneumonia bacteriana adquirida na comunidade. |
| SG11201902944TA (en) | 2016-11-07 | 2019-05-30 | Arbutus Biopharma Corp | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| US20190365788A1 (en) | 2016-11-21 | 2019-12-05 | Idenix Pharmaceuticals Llc | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases |
| WO2018112816A1 (zh) * | 2016-12-22 | 2018-06-28 | 高雄医学大学 | (2r，4r)-1，2，4-三羟基十七碳-16-炔在制备预防或治疗肝损伤医药组合物中的应用 |
| CN108276463A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一类新的化合物及其用途 |
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3059777C (en) | 2017-05-01 | 2023-02-21 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| AU2018280118B2 (en) * | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| US10688112B2 (en) | 2017-07-13 | 2020-06-23 | Emory University | Lipid disulfide prodrugs and uses related thereto |
| US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
| US11447512B2 (en) * | 2017-12-21 | 2022-09-20 | Shenzhen Targetrx, Inc. | Antiviral nucleoside reverse transcriptase inhibitor |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| TW202415643A (zh) | 2018-12-12 | 2024-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| WO2021035214A1 (en) | 2019-08-22 | 2021-02-25 | Emory University | Nucleoside prodrugs and uses related thereto |
| CN111330557B (zh) * | 2020-01-17 | 2022-11-18 | 中山职业技术学院 | 一种手性固定相及其制备和其在手性药物拆分应用 |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| CA3172483A1 (en) | 2020-04-06 | 2021-10-14 | Scott Ellis | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| PE20230618A1 (es) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | Analogos de nucleosido de 1'-ciano y usos de los mismos |
| BR112023000626A2 (pt) | 2020-07-16 | 2023-01-31 | Merck Sharp & Dohme Llc | Derivados de cianoenona cíclicos como moduladores de keap1 |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| WO2023250015A1 (en) * | 2022-06-21 | 2023-12-28 | The Children's Medical Center Corporation | Pyrimidine nucleoside treatments |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
| US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| US5401726A (en) * | 1988-08-25 | 1995-03-28 | Yoshitomi Pharaceutical Industries, Ltd. | 2'methylidenepyrimidine nucleoside compounds, their use and method for production thereof |
| DE4207363A1 (de) | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| FR2692265B1 (fr) * | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| GB9217998D0 (en) * | 1992-08-24 | 1992-10-07 | Wellcome Found | Methods of treating cancer |
| US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
| US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| WO1994005813A1 (en) | 1992-09-10 | 1994-03-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Compositions and methods for treatment of hepatitis c virus-associated diseases |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US5955591A (en) * | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US5627185A (en) * | 1994-11-23 | 1997-05-06 | Gosselin; Gilles | Acyclovir derivatives as antiviral agents |
| GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| PT831852E (pt) | 1995-06-07 | 2007-02-28 | Uab Research Foundation | Nucleósidos com actividade anti-vírus da hepatite b |
| US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
| AU7700098A (en) | 1997-05-29 | 1998-12-30 | Incara Pharmaceutical Corp. | Carbohydrate scaffold compounds and libraries |
| WO1999043691A1 (en) | 1998-02-25 | 1999-09-02 | Emory University | 2'-fluoronucleosides |
| US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| US6274725B1 (en) * | 1998-06-02 | 2001-08-14 | Isis Pharmaceuticals, Inc. | Activators for oligonucleotide synthesis |
| GB9821058D0 (en) | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| AU7361400A (en) * | 1999-09-08 | 2001-04-10 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| KR20030005197A (ko) | 2000-02-18 | 2003-01-17 | 샤이어 바이오켐 인코포레이티드 | 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법 |
| EP1964569A3 (en) | 2000-04-13 | 2009-07-22 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
| GB0011203D0 (en) | 2000-05-09 | 2000-06-28 | Univ Cardiff | Chemical compounds |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| WO2002004475A1 (en) * | 2000-07-07 | 2002-01-17 | The Research Foundation Of State University Of New York | 9-substituted adenine derivatives as prodrug regulators of cell and tissue function |
| US20020119443A1 (en) * | 2000-07-21 | 2002-08-29 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| WO2002044324A2 (en) | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| AU2002230398A1 (en) * | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| WO2002032920A2 (en) | 2000-10-18 | 2002-04-25 | Pharmasset Limited | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| CA2439836A1 (en) | 2001-03-01 | 2002-09-12 | Pharmasset, Inc. | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| US20040209831A1 (en) | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| JP2004534830A (ja) | 2001-06-21 | 2004-11-18 | グラクソ グループ リミテッド | Ｈｃｖにおけるヌクレオシド化合物 |
| EP1435974A4 (en) | 2001-09-28 | 2006-09-06 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES |
| US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| JP2005527499A (ja) | 2002-02-13 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法 |
| AU2003219817B2 (en) | 2002-02-20 | 2006-08-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus |
| WO2003072757A2 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
| JP2005524662A (ja) | 2002-02-28 | 2005-08-18 | ビオタ インコーポレーティッド | ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ |
| US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
| AU2003241621A1 (en) | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| WO2003105770A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2004000858A2 (en) | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| EP1572945A2 (en) | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| CN1678326A (zh) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| PL374792A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| EP1556399A4 (en) | 2002-07-16 | 2007-09-26 | Merck & Co Inc | Nucleoside derivatives as inhibitors of RNA-dependent viral RNA polymerase |
| WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
| EP1529172A1 (de) | 2002-08-15 | 2005-05-11 | DOW CORNING GmbH | Zusammensetzung und vorrichtung zum dämpfen mechanischer bewegung |
| CA2496547A1 (en) | 2002-08-29 | 2004-03-11 | University Of Southampton | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| RU2005108601A (ru) | 2002-09-26 | 2006-01-20 | Эл Джи Лайф Сайенсиз Лтд. (Kr) | (+)-транс-изомеры(1-фосфонометокси-2-алкилциклопропил)метилнуклеозидные производные, способ получения их стереоизомеров и применение указанных соединений в качестве противовирусных средств |
| US20040229840A1 (en) * | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| LT1576138T (lt) | 2002-11-15 | 2017-06-26 | Idenix Pharmaceuticals Llc | 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija |
| TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
| US7741065B2 (en) | 2003-03-13 | 2010-06-22 | Ramot At Tel Aviv University Ltd. | Non-invasive marker for liver function and disease |
| WO2004096237A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| MXPA05011294A (es) | 2003-04-25 | 2006-03-15 | Gilead Sciences Inc | Compuestos de fosfonato anti-inflamatorios. |
| KR20060022647A (ko) | 2003-04-25 | 2006-03-10 | 길리애드 사이언시즈, 인코포레이티드 | 키나아제 억제 포스포네이트 유사체 |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| EP1656093A2 (en) | 2003-05-14 | 2006-05-17 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| HUE029877T2 (en) | 2003-05-30 | 2017-04-28 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
| JP2006527719A (ja) | 2003-06-19 | 2006-12-07 | エフ．ホフマン−ラ ロシュ アーゲー | ４’−アジドヌクレオシド誘導体の調製方法 |
| US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| NZ546055A (en) | 2003-08-27 | 2010-05-28 | Biota Scient Management | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| CA2543116A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| US20050190302A1 (en) * | 2004-02-26 | 2005-09-01 | Goedde Kirby R. | Automation of field service color temperature alignment |
| WO2005087788A2 (en) | 2004-03-04 | 2005-09-22 | The Regents Of The University Of California | Methods for preparation of nucleoside phosphonate esters |
| CA2571675A1 (en) | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| CA2571079A1 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2348029A1 (en) | 2004-07-21 | 2011-07-27 | Pharmasset, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
| WO2006021341A1 (en) | 2004-08-23 | 2006-03-02 | F. Hoffmann-La Roche Ag | Antiviral 4’-azido-nucleosides |
| EP1804812A4 (en) | 2004-10-21 | 2009-09-02 | Merck & Co Inc | FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS |
| WO2006063149A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| AR058419A1 (es) | 2005-02-28 | 2008-02-06 | Gilead Sciences Inc | Compuestos de nucleosidos triciclicos para tratar infecciones virales |
| CA2600886A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| JP2008535932A (ja) | 2005-03-09 | 2008-09-04 | イデニクス（ケイマン）リミテツド | 抗ウィルス剤としての非天然塩基を有するヌクレオシド |
| US7405204B2 (en) * | 2005-04-25 | 2008-07-29 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| US8207136B2 (en) | 2005-04-26 | 2012-06-26 | The Board Of Trustees Of The University Of Illinois | Nucleoside compounds and methods of use thereof |
| US7776550B2 (en) * | 2005-05-05 | 2010-08-17 | Philadelphia Health & Education Corporation | Diagnosis of liver pathology through assessment of protein glycosylation |
| WO2006122207A1 (en) * | 2005-05-10 | 2006-11-16 | Valeant Research & Development | 6-hydrazinopurine 2'-methyl ribonucleosides and nucleotides for treatment of hcv |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| WO2007020193A2 (en) | 2005-08-15 | 2007-02-22 | F. Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4 ' -substituted pronucleotides |
| ES2422290T3 (es) | 2005-12-23 | 2013-09-10 | Idenix Pharmaceuticals Inc | Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados |
| EP1987050A2 (en) | 2006-02-14 | 2008-11-05 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CN101333235A (zh) | 2007-06-29 | 2008-12-31 | 天津大学 | 一种糖基部分具有乙炔基及氟原子取代的核苷衍生物 |
| GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
| EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| WO2012142093A2 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| JP6165848B2 (ja) | 2012-05-22 | 2017-07-19 | イデニク ファーマシューティカルズ エルエルシー | 肝疾患のためのｄ−アミノ酸化合物 |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| EP2906579B1 (en) | 2012-10-08 | 2018-04-18 | Idenix Pharmaceuticals LLC. | 2'-chloro nucleoside analogs for hcv infection |
| US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| EP2909209B1 (en) | 2012-10-17 | 2022-08-03 | Merck Sharp & Dohme LLC | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| EP2909223B1 (en) | 2012-10-19 | 2017-03-22 | Idenix Pharmaceuticals LLC | Dinucleotide compounds for hcv infection |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
| US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| US9765107B2 (en) | 2013-06-18 | 2017-09-19 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
-
2007
- 2007-12-27 US US12/005,938 patent/US20080261913A1/en not_active Abandoned
- 2007-12-27 US US12/005,937 patent/US7951789B2/en active Active
- 2007-12-28 JP JP2009544100A patent/JP5578853B2/ja not_active Expired - Fee Related
- 2007-12-28 NZ NZ577999A patent/NZ577999A/en not_active IP Right Cessation
- 2007-12-28 KR KR1020097015742A patent/KR101508018B1/ko not_active Expired - Fee Related
- 2007-12-28 WO PCT/US2007/026408 patent/WO2008082601A2/en not_active Ceased
- 2007-12-28 EP EP07872645.2A patent/EP2120566B1/en active Active
- 2007-12-28 MX MX2009006851A patent/MX2009006851A/es active IP Right Grant
- 2007-12-28 EP EP07868086A patent/EP2107909A4/en not_active Withdrawn
- 2007-12-28 SG SG2011096476A patent/SG177923A1/en unknown
- 2007-12-28 CA CA002673722A patent/CA2673722A1/en not_active Abandoned
- 2007-12-28 TW TW096150931A patent/TW200844108A/zh unknown
- 2007-12-28 CA CA002673776A patent/CA2673776A1/en not_active Abandoned
- 2007-12-28 BR BRPI0720637-2A2A patent/BRPI0720637A2/pt active Search and Examination
- 2007-12-28 WO PCT/US2007/026409 patent/WO2008082602A2/en not_active Ceased
- 2007-12-28 ME MEP-2009-232A patent/ME00816B/me unknown
- 2007-12-28 AU AU2007339226A patent/AU2007339226B2/en not_active Ceased
- 2007-12-28 MY MYPI20092752A patent/MY169568A/en unknown
- 2007-12-28 TW TW096150890A patent/TWI412368B/zh not_active IP Right Cessation
- 2007-12-28 RU RU2012132218/04A patent/RU2525392C2/ru not_active IP Right Cessation
- 2007-12-28 UA UAA200907835A patent/UA96975C2/uk unknown
- 2007-12-28 JP JP2009544101A patent/JP2010514769A/ja active Pending
-
2008
- 2008-04-25 US US12/150,327 patent/US7902202B2/en active Active
-
2009
- 2009-07-08 NO NO20092585A patent/NO20092585L/no not_active Application Discontinuation
- 2009-07-28 IL IL200116A patent/IL200116A0/en unknown
-
2011
- 2011-05-26 US US13/116,890 patent/US8691788B2/en active Active
-
2014
- 2014-03-04 US US14/197,078 patent/US9249173B2/en active Active
- 2014-03-24 JP JP2014060859A patent/JP2014139218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514768A5 (enExample) | ||
| RU2012132218A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| JP2013523765A5 (enExample) | ||
| ES2963716T3 (es) | Profármacos de nucleósido fosforamidato | |
| ES2458358T3 (es) | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas | |
| JP2012519691A5 (enExample) | ||
| JP2018500372A5 (enExample) | ||
| HUP0301730A2 (hu) | Nukleozid vegyületek és ezek alkalmazása | |
| JP2004533401A5 (enExample) | ||
| CA2389745A1 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
| TW201217392A (en) | Substituted nucleotide analogs | |
| JP2015512860A5 (enExample) | ||
| TR201906767T4 (tr) | Modifiye florlanmış nükleosit analogları. | |
| WO2017156262A1 (en) | Acyclic antivirals | |
| JP2016503800A5 (enExample) | ||
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| JP2014526474A (ja) | ウイルス感染の治療のための化合物および薬学的組成物 | |
| CA2818853A1 (en) | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus | |
| JP2007501185A5 (enExample) | ||
| RU2008152171A (ru) | Новые ингибиторы вирусной репликации гепатита с | |
| RU2010112408A (ru) | Фосфадиазиновые ингибиторы iv полимеразы hcv | |
| RU2012117395A (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| RU2008117157A (ru) | Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с | |
| CN101626683B (zh) | 用于治疗病毒感染的化合物和药物组合物 | |
| RU2009128978A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций |